Skip to content

BMY

Bristol-Myers Squibb Company

Revenue by product

2025, ended Dec 31, 2025

Earlier:

Products by fiscal year

Products by fiscal year
Line, in USD20252024202320222021202020192018201720162015201420132012201120102009
Eliquis14.4B13.3B—11.8B10.8B9.2B7.9B6.4B4.9B3.3B1.9B774M146M2.0M———
Opdivo10.0B9.3B—8.2B7.5B7.0B7.2B6.7B4.9B3.8B942M6.0M—————
Orencia3.71B3.68B3.60B3.46B3.31B3.16B2.98B2.71B2.48B2.27B1.89B1.65B1.44B1.18B0.92B0.73B0.60B
Breyanzi1.36B0.75B0.36B0.18B87M————————————
Alliance and other revenues1.44B—1.23B1.49B1.33B————————————
Sprycel0.49B1.29B1.93B——2.14B2.11B2.00B2.01B1.82B1.62B1.49B1.28B1.02B0.80B0.58B0.42B
Yervoy2.90B2.53B2.24B2.13B2.03B1.68B1.49B1.33B1.24B1.05B1.13B1.31B0.96B0.71B0.36B——
Abecma427M406M472M388M164M————————————
Other Growth products1.92B1.64B1.21B1.09B—————————————
Camzyos1.07B0.60B0.23B24M—————————————
Opdivo Qvantig238M————————————————
Other Legacy products0.80B0.93B0.96B1.16B—————————————
Sotyktu291M246M170M8.0M—————————————
Krazati205M126M———————————————
Other revenues992M—620M746M614M————————————
Alliance revenues447M——742M716M————————————
7.4B13.5B32.0B14.7B19.8B19.4B4.4B3.3B5.2B7.2B9.1B10.6B12.6B14.7B19.2B18.2B17.8B
Total48.2B48.3B45.0B46.2B46.4B42.5B26.1B22.6B20.8B19.4B16.6B15.9B16.4B17.6B21.2B19.5B18.8B